Barclays upgraded Deciphera to Equal Weight from Underweight with a $26 price target after the company entered into a definitive merger agreement with Ono Pharmaceutical for Ono to acquire Deciphera for $25.60 per share through a tender offer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Questions or Comments about the article? Write to editor@tipranks.com